Critical Review: Vitae Pharmaceuticals (NASDAQ:VTAE) & Argos Therapeutics (ARGS)

Argos Therapeutics (NASDAQ: ARGS) and Vitae Pharmaceuticals (NASDAQ:VTAE) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.


This table compares Argos Therapeutics and Vitae Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Argos Therapeutics -13,750.64% N/A -120.95%
Vitae Pharmaceuticals -318,350.20% -53.70% -49.85%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Argos Therapeutics and Vitae Pharmaceuticals, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Argos Therapeutics 0 0 0 0 N/A
Vitae Pharmaceuticals 0 0 0 0 N/A

Argos Therapeutics currently has a consensus target price of $24.00, indicating a potential upside of 1,820.00%. Given Argos Therapeutics’ higher possible upside, analysts clearly believe Argos Therapeutics is more favorable than Vitae Pharmaceuticals.

Valuation and Earnings

This table compares Argos Therapeutics and Vitae Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Argos Therapeutics $950,000.00 8.08 -$53.02 million ($25.20) -0.05
Vitae Pharmaceuticals N/A N/A N/A ($1.92) -10.94

Vitae Pharmaceuticals has lower revenue, but higher earnings than Argos Therapeutics. Vitae Pharmaceuticals is trading at a lower price-to-earnings ratio than Argos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

72.6% of Vitae Pharmaceuticals shares are owned by institutional investors. 28.2% of Argos Therapeutics shares are owned by insiders. Comparatively, 14.8% of Vitae Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.


Argos Therapeutics beats Vitae Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

Argos Therapeutics Company Profile

Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.

Vitae Pharmaceuticals Company Profile

Vitae Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on discovering and developing small molecule drugs for diseases. It is engaged in developing a portfolio of product candidates through Contour, its structure-based drug discovery platform. The Company’s product candidates include VTP- 43742 for the treatment of psoriasis, as well as multiple other autoimmune disorders. The Company completed approximately two Phase I studies with VTP-43742. Its VTP-38543, a second product candidate is in a Phase IIa proof-of-concept clinical trial for the treatment of atopic dermatitis. Its VTP-36951 is for the treatment and prevention of Alzheimer’s disease, or Alzheimer’s. VTP-43742, the Company’s wholly owned clinical candidate in an on-going Phase IIa proof-of-concept trial in psoriasis, is an orally active small molecule inhibitor of Retinoic acid-receptor (RAR)-Related Orphan Receptor gamma-t (RORgt) activity for the treatment of various autoimmune disorders.

Receive News & Ratings for Argos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply